Invention Grant
US08048923B2 Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides
有权
治疗由扩大基因组CAG核苷酸引起的多聚谷氨酰胺病症
- Patent Title: Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides
- Patent Title (中): 治疗由扩大基因组CAG核苷酸引起的多聚谷氨酰胺病症
-
Application No.: US10758415Application Date: 2004-01-16
-
Publication No.: US08048923B2Publication Date: 2011-11-01
- Inventor: William S. Brusilow
- Applicant: William S. Brusilow
- Applicant Address: US MD Chevy Chase
- Assignee: Odessa Pharma
- Current Assignee: Odessa Pharma
- Current Assignee Address: US MD Chevy Chase
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- Main IPC: A61K31/198
- IPC: A61K31/198
Abstract:
The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain α-keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.
Public/Granted literature
- US20040152778A1 Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides Public/Granted day:2004-08-05
Information query
IPC分类:
